Preclinical and clinical evidence of Nurr1 involvement in neurodegenerative diseases such as AD, PD and MS has fueled the development of Nurr1 agonists as potential therapeutics in neurodegeneration2,4,6,7. Here, NR4A2 is linked to myeloid sarcoma.